Current report No. 17/2021 – Signing of a co-funding agreement with the National Centre for Research regarding a project for an inhaled drug candidate for the treatment of inflammatory and fibrotic lung diseases, including COVID-19 complications

Current reports March, 31 2021

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) - confidential information.
Date: March 31, 2021, 08:51 AM

Content of the report:   

With reference to current report No. 7/2021 of February 10, 2021 on the selection by the National Centre for Research and Development (“NCBR”) for co-funding of the following project: “In vivo validation, toxicological development and implementation into clinical trials and the Company’s activities of an inhalation drug candidate for the treatment of inflammatory and fibrotic lung diseases including COVID-19 complications” submitted to a competition under the Smart Growth Operational Programme 2014-2020, measure 1.1/submeasure 1.1.1., the Management Board of Celon Pharma S.A. hereby informs that on March 30, 2021 was informed that the NCRD signed a co-funding agreement for the above-mentioned project.

Pursuant to the co-funding agreement, the total cost of the project amounts to PLN 46.9 million, and the amount of co-funding granted amounts to PLN 27.2 million. Pursuant to the co-funding agreement, the total cost of the project amounts to PLN 46.9 million, and the amount of co-funding granted amounts to PLN 27.2 million. The period of cost eligibility for the project ends on December 31, 2023.

Detailed information on the project was provided in the aforementioned current report No. 7/2021.